DivGro is now DivGro 2.0!

DivGro moved to another platform and is now DivGro 2.0!

Please enjoy complimentary access to all the content on DivGro 2.0 until I formally launch it! You can sign up for free and join more than 1,100 existing members!

All content will be complimentary until the formal launch of DivGro 2.0. This includes my monthly newsletter and articles like
 How to Assess Dividend Quality and The Chowder Ruleand a live spreadsheet of my DivGro Portfolio.

Read more About DivGro 2.0 ...

Sunday, March 20, 2016

Recent Buy: Gilead Sciences, Inc.


March 18, 2016: Bought 28 shares of GILD at $90.47 per share.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The company’s primary areas of focus include human immunodeficiency virus, liver diseases such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. GILD markets its products through commercial teams and in conjunction with third-party distributors and corporate partners. The company was founded in 1987 and is headquartered in Foster City, California.

I already own 22 shares of GILD, which I transferred in December 2015 from my Scottrade to DivGro. Adding 28 shares brings my total holding to 50 shares. Because I'm dollar-cost averaging down, my cost basis is reduced to $101.91 and average yield on cost increases to 1.69%.

GILD only recently started paying dividends. The company pays 43¢ per quarter, which equates to 1.90% at my buy price. So far, the company has paid 3 quarterly dividends and is scheduled to pay the next quarterly dividend on March 30.

Below is a chart showing my buy prices:


The drop in GILD's share price is pushing up yield to nearly 2%, which is not to bad for a company that just started paying dividends. My main motivation for owning GILD is the company's growth prospects. Over time, though, I believe the dividend yield will increase to more attractive levels.


Following is a table containing updated ratings of GILD from various sources:

 Dividend.com's DARS Rating 3.5/5 (Recommended)
 S&P Capital IQ's Stock Report (*****Strong Buy
 Thomson Reuters StockReport+  (7/10) Neutral  
 The Motley Fool's CAPS Rating (*****) 
 MorningStar Rating (*****)
 Zacks Rank (Style Score)  1-Strong Buy (VGM:B)
 †combined Value/Growth/Momentum score


According to Morningstar, GILD has a fair value of $128.00, so I bought shares at a great discount!

28 shares of GILD adds $48.16 to DivGro's projected annual dividend income.

Do you own shares of GILD? With no record of dividend growth, but fantastic EPS growth, do you think GILD is a good dividend growth prospect? Please share your comments below.

4 comments :

  1. "I have a small spanish dividend growth investment portfolio. I am looking to diversy with international stocks. Which 3 - 5 stocks should you recommend for a long term dividend investment strategy?
    Thanks in advance
    "

    ReplyDelete
    Replies
    1. I don't like to recommend stocks, since every investor's situation is so different. My watch list contains stocks from the CCC list that pass a series of filters. Every month I narrow the list down to 10 stocks to consider -- again, these are not recommendations but a short list for consideration. My March list will be published on Seeking Alpha soon (with a post here linking to it).

      Take care,
      FerdiS

      Delete
  2. I a fan of GILD. This stock has been good to me since I added it to my portfolio last summer.

    ReplyDelete
    Replies
    1. Thanks for visiting and sharing, Investment Hunting. GILD is a new dividend payer, but I think over time it should become a big winner!

      Delete

Please don't include links in comments. I will mark such comments as spam and the comment won't be published. To make me aware of your blog or website, comment on my Blogrole page instead.

Subscribe to Portfolio Insight and Save!

Use my affiliate link to sign up for a free 14-day, no-obligation trial of Portfolio Insight. No credit card required. If you decide to subscribe during the trial period, you'll receive a 20% discount on the first year's annual subscription price of $330. Please note the 20% affiliate discount does not apply to the monthly rate.